[HTML][HTML] Heart failure secondary to myocarditis after SARS-CoV-2 reinfection: a case report

PG Riedel, VF Sakai, SCC Toniasso, MCB Brum… - International Journal of …, 2021 - Elsevier
PG Riedel, VF Sakai, SCC Toniasso, MCB Brum, FS Fernandes, RM Pereira, CP Baldin…
International Journal of Infectious Diseases, 2021Elsevier
Introduction Cardiac involvement in COVID-19 can range from mild damage to severe
myocarditis. The precise mechanism by which COVID-19 causes myocardial injury is still
unknown. Myocarditis following administration of COVID-19 vaccines, especially those
based on mRNA, has also been described. However, no reports of heart failure following
reinfection with SARS-CoV-2 in patients immunized with an inactivated vaccine have been
identified. Case description The patient was a 47-year-old male construction worker of …
Introduction
Cardiac involvement in COVID-19 can range from mild damage to severe myocarditis. The precise mechanism by which COVID-19 causes myocardial injury is still unknown. Myocarditis following administration of COVID-19 vaccines, especially those based on mRNA, has also been described. However, no reports of heart failure following reinfection with SARS-CoV-2 in patients immunized with an inactivated vaccine have been identified.
Case description
The patient was a 47-year-old male construction worker of African descent, with type II diabetes and a history of infection by SARS-CoV-2 in December 2020 and May 2021, confirmed by RT-PCR. He received two doses of an inactivated vaccine against COVID-19. Between the two COVID-19 episodes with positive RT-PCR, he had two episodes of bacterial lung infection. After the second episode of SARS-CoV-2 infection, he was diagnosed with severe heart failure as a sequela of myocarditis.
Conclusion
It is essential to perform a thorough follow-up after infection with SARS-CoV-2 since, even with proper immunization, it is possible that the patient was reinfected and suffered severe cardiac sequelae as a consequence. The hypothesis of an etiology associated with the use of an inactivated vaccine against COVID-19, with a potential immune enhancement mechanism following reinfection with SARS-CoV-2, cannot be rejected.
Elsevier